Duvelisib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 181 publications
Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.
Journal: Blood advances
Published: January 29, 2026
Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability.
Journal: Analytical methods : advancing methods and applications
Published: January 26, 2026
Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.
Journal: American journal of clinical dermatology
Published: December 01, 2025
Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.
Journal: Biochemical and biophysical research communications
Published: December 01, 2025
Duvelisib upregulates p27 expression and leads to intestinal damage via the NEDD4L/CK1ε axis.
Journal: Biochemical pharmacology
Published: November 01, 2025
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.
Journal: European journal of haematology
Published: August 22, 2025
Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.
Journal: Cureus
Published: August 18, 2025
Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.
Journal: Clinical drug investigation
Published: June 24, 2025
Human Serum Albumin-Lipid Nanocapsules of Duvelisib for Hematological Cancers: Characterization, In-Vitro Cell-Culture, Toxicity and Pharmacokinetic Studies.
Journal: AAPS PharmSciTech
Published: June 21, 2025
Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.
Journal: Cell death discovery
Published: May 21, 2025
A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects.
Journal: American journal of cancer research
Published: March 20, 2025
Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.
Journal: Journal of cutaneous medicine and surgery
Published: March 12, 2025
Last Updated: 04/28/2026